Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BIOC | Biocept, Inc.

Index- P/E- EPS (ttm)-50.69 Insider Own9.21% Shs Outstand2.63M Perf Week-6.58%
Market Cap3.41M Forward P/E- EPS next Y-1.38 Insider Trans0.00% Shs Float2.63M Perf Month37.86%
Income-30.60M PEG- EPS next Q- Inst Own10.10% Short Float / Ratio0.61% / 0.01 Perf Quarter-8.97%
Sales1.40M P/S2.43 EPS this Y-890.30% Inst Trans-43.42% Short Interest0.02M Perf Half Y-84.22%
Book/sh0.28 P/B5.07 EPS next Y75.10% ROA- Target Price- Perf Year-94.08%
Cash/sh2.75 P/C0.52 EPS next 5Y40.00% ROE- 52W Range0.80 - 29.18 Perf YTD-91.07%
Dividend- P/FCF- EPS past 5Y61.00% ROI-281.90% 52W High-95.13% Beta0.72
Dividend %- Quick Ratio1.70 Sales past 5Y38.50% Gross Margin- 52W Low77.50% ATR0.19
Employees50 Current Ratio1.80 Sales Q/Q-89.70% Oper. Margin- RSI (14)57.87 Volatility13.88% 14.51%
OptionableNo Debt/Eq7.00 EPS Q/Q80.30% Profit Margin- Rel Volume0.05 Prev Close1.48
ShortableNo LT Debt/Eq2.67 EarningsAug 14 AMC Payout- Avg Volume1.91M Price1.42
Recom3.00 SMA2023.09% SMA5020.87% SMA200-82.98% Volume104,019 Change-4.05%
Date Action Analyst Rating Change Price Target Change
Nov-14-17Reiterated Chardan Capital Markets Buy $2.50 → $1.50
Jun-02-17Initiated Chardan Capital Markets Buy $2.50
Jun-06-16Initiated ROTH Capital Buy $1.20
Aug-19-15Initiated H.C. Wainwright Buy $4
Jun-03-14Initiated Aegis Capital Buy $16
Sep-21-23 08:00AM
Sep-08-23 11:18AM
Sep-05-23 08:00AM
08:00AM Loading…
Aug-25-23 08:00AM
Aug-14-23 04:05PM
Aug-01-23 07:06AM
Jul-13-23 06:15PM
Jun-20-23 04:15PM
Jun-14-23 04:05PM
Jun-05-23 08:00AM
May-24-23 08:39PM
08:00AM Loading…
May-17-23 08:00AM
May-12-23 06:02AM
May-10-23 04:05PM
Apr-19-23 01:28PM
Apr-17-23 04:10PM
Mar-24-23 08:00AM
Mar-01-23 08:00AM
Jan-31-23 07:54AM
Jan-06-23 06:55AM
Dec-25-22 12:06PM
Nov-21-22 04:05PM
Nov-18-22 08:00AM
Nov-16-22 08:00AM
Nov-10-22 04:05PM
Oct-19-22 08:00AM
08:00AM Loading…
Oct-17-22 08:00AM
Oct-14-22 08:00AM
Oct-06-22 08:00AM
Aug-31-22 04:31PM
Aug-22-22 04:15PM
Aug-16-22 08:00AM
Jun-27-22 08:00AM
Jun-22-22 07:30AM
Jun-07-22 08:00AM
May-23-22 04:05PM
May-16-22 04:05PM
Apr-08-22 04:05PM
Apr-06-22 08:00AM
Mar-31-22 06:15PM
Mar-18-22 08:00AM
Mar-08-22 08:17AM
Mar-04-22 08:00AM
Feb-22-22 04:17PM
Feb-18-22 04:54AM
Feb-16-22 04:05PM
Feb-10-22 08:17AM
Jan-21-22 08:00AM
Jan-07-22 09:40AM
Jan-04-22 08:00AM
Dec-09-21 08:17AM
Dec-03-21 06:49AM
Nov-22-21 01:56PM
Nov-18-21 02:45PM
Nov-15-21 04:05PM
Nov-09-21 08:17AM
Nov-08-21 08:00AM
Oct-06-21 08:00AM
Sep-29-21 01:28PM
Sep-22-21 08:17AM
Sep-21-21 08:17AM
Sep-07-21 08:00AM
Aug-31-21 08:00PM
Aug-22-21 08:17AM
Aug-19-21 11:37AM
Aug-17-21 11:22AM
Aug-16-21 04:05PM
Aug-09-21 08:00AM
Aug-03-21 08:17AM
Jul-21-21 08:17AM
Jul-20-21 08:17AM
Jul-19-21 08:00AM
Jul-06-21 08:27AM
Jun-28-21 08:05AM
Jun-22-21 08:17AM
Jun-15-21 08:17AM
Jun-09-21 08:37AM
Jun-03-21 08:00AM
Jun-02-21 04:05PM
May-12-21 04:05PM
May-05-21 08:00AM
Apr-28-21 08:17AM
Apr-21-21 08:17AM
Apr-14-21 08:05AM
Apr-07-21 04:05PM
Apr-01-21 05:00PM
Mar-30-21 08:06AM
Mar-29-21 04:32PM
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.